ATC Group: H03BB02 Thiamazole

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of H03BB02 in the ATC hierarchy

Level Code Title
1 H Systemic hormonal preparations, excl. Sex hormones and insulins
2 H03 Thyroid therapy
3 H03B Antithyroid preparations
4 H03BB Sulfur-containing imidazole derivatives
5 H03BB02 Thiamazole

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 10 mg

Active ingredients in H03BB02

Active Ingredient Description
Thiamazole

Thiamazole inhibits dose-dependently the incorporation of iodine into tyrosine and thereby the neosynthesis of thyroid hormones. This property permits symptomatic therapy of hyperthyroidism regardless of its cause.

Related product monographs

Title Information Source Document Type  
TAPAZOLE Tablet FDA, National Drug Code (US) MPI, US: SPL/Old

Medicines in this ATC group

United States (US)

Brazil (BR)

Canada (CA)

Croatia (HR)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

France (FR)

Germany (DE)

Hong Kong (HK)

Israel (IL)

Japan (JP)

Lithuania (LT)

Mexico (MX)

Netherlands (NL)

Poland (PL)

Romania (RO)

Singapore (SG)

Spain (ES)

Tunisia (TN)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.